Pura Vida Investments, LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 13, 2025), Pura Vida Investments, LLC reported 8 stock positions worth $16.6 million. Its top holding was Beta Bionics (BBNX) at 37.6% of the portfolio, followed by Insight Molecular Diagnostic (IMDX, 17.2%) and Caris Life Sciences (CAI, 14.5%). Compared with Q1 2025, it opened 1 new position, sold out of 1, added to 4 and reduced 2. The biggest buy was a new position in Caris Life Sciences (CAI) and the biggest sale an exit from Kestra Medical Technologies (KMTS).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001590144
- Portfolio Value
- $16.6M (Q2 2025)
- SEC Filing
- 0001590144-25-000006 ↗ filed Aug 13, 2025
Holdings Value
Holdings 8 stocks · $16.6M
| BBNX Beta Bionics Inc. | 37.57% | 2,500 | $6.2M | Reduce -99.4% |
| IMDX Insight Molecular Diagnostic | 17.20% | 18,700 | $2.9M | Reduce -98.0% |
| CAI Caris Life Sciences Inc. | 14.45% | 45,000 | $2.4M | New |
| ESTA Establishment Labs Holdings | 11.56% | 89,940 | $1.9M | Add +99.9% |
| OM Outset Medical Inc. | 8.18% | 429,120 | $1.4M | Add +8482.4% |
| NSPR Inspiremd Inc. | 6.15% | 450,517 | $1.0M | No change |
| NTRA Natera Inc. | 2.54% | 245,691 | $422K | Add +9727.6% |
| MGX Metagenomi Therapeutics Inc. | 2.35% | 952,134 | $391K | Add +260.1% |
Portfolio Sells Q1 2025 → Q2 2025
Portfolio Buys Q1 2025 → Q2 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 19 | $37.0M | ALMR, BBNX, ESTA, IMDX, NVDA |
| Q1 2026 | 17 | $14.9M | IMDX, BBNX, ESTA, CAI, NSPR |
| Q4 2025 | 18 | $26.8M | BBNX, IMDX, ESTA, CAI, NSPR |
| Q3 2025 | 8 | $16.4M | BBNX, IMDX, CAI, ESTA, NSPR |
| Q2 2025 | 8 | $16.6M | BBNX, IMDX, CAI, ESTA, OM |
| Q1 2025 | 8 | $13.7M | BBNX, IMDX, ESTA, NSPR, KMTS |
| Q4 2024 | 9 | $18.1M | ESTA, MSOS, LUNG, QTRX, IMDX |
| Q3 2024 | 16 | $60.8M | MSOS, ESTA, GKOS, NTRA, ISRG |
| Q2 2024 | 25 | $82.7M | ESTA, GKOS, ISRG, NTRA, MSOS |
| Q1 2024 | 30 | $146.8M | EXAS, ESTA, ISRG, QTRX, LYRA |